Divergent genomic evolution in astrocytomas and oligodendrogliomas.

Genomic evolution in IDH-mutant gliomas diverges between astrocytomas and oligodendrogliomas, with distinct genetic alterations linked to tumor progression and treatment response.

• Why it matters: Understanding the genetic drivers of glioma progression is crucial for improving treatment strategies, as these tumors show variable responses and develop resistance over time.
• What they did: Whole-genome and whole-exome sequencing of 183 longitudinal tumor samples revealed known markers like CDKN2A/B deletions and identified new alterations such as PI3K and NOTCH1 mutations in oligodendrogliomas, and oncogene amplifications in astrocytomas.
• The result: Both tumor types exhibit convergent genetic changes associated with worse outcomes, with oligodendrogliomas and astrocytomas adapting differently to treatment-induced DNA damage, highlighting distinct evolutionary pathways.